Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 185-187

  Gruson, Damien ^a,b   Ferracin, Benjamin ^a,b   Ahn, Sylvie A ^a,b   Rousseau, Michel F ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Biomarker; BNP; FGF 23; Galectin 3; Heart failure; NT proBNP; Prognosis; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; EDETIC ACID; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3; SOLUBLE PROTEIN ST2; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR; IL1RL1 PROTEIN, HUMAN;

AGE; AGED; ARTICLE; COMPARATIVE STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BIOMARKERS; FEMALE; FIBROBLAST GROWTH FACTORS; GALECTIN 3; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS;

EID: 84929457552     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.074     Document Type: Article

References (9)

1. D. Gruson, T. Lepoutre, S.A. Ahn, M.F. Rousseau, Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction, Int. J. Cardiol. 172 (1) (2014) e250-e252.
2. C.W. Yancy, M. Jessup, B. Bozkurt, F.A. Masoudi, J. Butler, P.E. McBride, D.E. Casey Jr., J.J. McMurray, M.H. Drazner, J.E. Mitchell, G.C. Fonarow, P.N. Peterson, S.A. Geraci, T. Horwich, J.L. Januzzi, M.R. Johnson, E.K. Kasper, W.C. Levy, B. Riegel, F. Sam, L.W. Stevenson, W.H. Tang, E.J. Tsai, B.L. Wilkoff, 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol. 13 (2013) 10.
3. E. Zamora, J. Lupon, M. de Antonio, A. Galan, M. Domingo, A. Urrutia, M. Troya, A. Bayes-Genis, Renal function largely influences Galectin-3 prognostic value in heart failure, Int. J. Cardiol. 177 (1) (2014) 171-177.
4. O.M. Gutierrez, M. Mannstadt, T. Isakova, J.A. Rauh-Hain, H. Tamez, A. Shah, K. Smith, H. Lee, R. Thadhani, H. Juppner, M. Wolf, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis, N. Engl. J. Med. 359 (6) (2008) 584-592.
5. M.A. Mirza, A. Larsson, H. Melhus, L. Lind, T.E. Larsson, Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population, Atherosclerosis 207 (2) (2009) 546-551.
6. S. Seiler, B. Cremers, N.M. Rebling, F. Hornof, J. Jeken, S. Kersting, C. Steimle, P. Ege, M. Fehrenz, K.S. Rogacev, B. Scheller, M. Bohm, D. Fliser, G.H. Heine, The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation, Eur. Heart J. 32 (21) (2011) 2688-2696.
7. D. Gruson, T. Lepoutre, J.M. Ketelslegers, J. Cumps, S.A. Ahn, M.F. Rousseau, C-terminal FGF23 is a strong predictor of survival in systolic heart failure, Peptides 37 (2) (2012) 258-262.
8. S. Liu, R. Guo, L.G. Simpson, Z.S. Xiao, C.E. Burnham, L.D. Quarles, Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX, J. Biol. Chem. 278 (39) (2003) 37419-37426.
9. G.Li,S.Oparil,S.S.Kelpke,Y.F.Chen,J.A.Thompson, Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro, Circulation 106 (7) (2002) 854-859.